Welcome to our dedicated page for Addex Therapeutics SEC filings (Ticker: ADXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Addex Therapeutics Ltd. filings document a foreign private issuer and ADR-linked clinical-stage biotechnology company focused on small-molecule allosteric modulators. Form 6-K reports furnish press releases, financial results, interim condensed consolidated financial statements, MD&A, iXBRL exhibits, and risk-factor updates incorporated into Form F-3 and Form S-8 registration statements.
The disclosures cover pipeline programs such as GABAB PAM candidates, mGlu receptor modulators, ADX71149, and Neurosterix-related NTX-253, along with collaboration and licensing arrangements, strategic investments, cash resources, governance, equity-plan registrations, and foreign-issuer reporting under Form 20-F.
Addex Therapeutics Ltd reported that shareholders approved all Board of Directors’ proposals at the 2026 Annual General Meeting. The votes represented 29.35% of the company’s outstanding capital, confirming support for the 2025 annual report, consolidated and statutory financial statements, and the compensation report.
Shareholders approved compensation for the board and executive management and granted discharge to both for their 2025 activities. All current board members, including Chairman Dr. Vincent Lawton, were re-elected, as were BDO SA as auditor for the 2026 business year and Robert P. Briner as independent voting rights representative until the 2027 AGM.
Investors also backed amendments to the Articles of Association related to an increase of the capital band and conditional share capital, preserving flexibility for future equity-related actions. The filing reiterates the company’s focus on allosteric modulators for neurological disorders and notes its 20% equity interest in Neurosterix US Holdings LLC.
Addex Therapeutics Ltd reports unaudited Q1 2026 results showing a small, lean operation but serious funding pressure. The company generated no revenue and recorded a net loss of CHF 1.71 million, largely driven by operating loss of CHF 0.48 million and a CHF 1.23 million share of losses from its 20% stake in Neurosterix.
Cash and cash equivalents fell to CHF 0.94 million as of March 31, 2026 after negative operating cash flow of CHF 0.77 million, only partly offset by CHF 0.07 million of cash from selling treasury shares. The company explicitly states its cash is expected to fund operations only through the end of July 2026, and concludes that there is a material uncertainty raising substantial doubt about its ability to continue as a going concern without new capital or monetization of assets.
Addex Therapeutics Ltd filed a Form 6-K announcing that its 2026 Annual General Meeting will be held on June 29, 2026 at 11:00 am CEST at Campus Biotech in Geneva. Shareholders will be asked to approve the 2025 annual and consolidated financial statements, vote consultatively on the 2025 compensation report, decide on appropriation of results and grant discharge to the board and executive management.
The agenda also includes re-elections of all current board members and the chairman, re-elections to the Compensation Committee, re-appointment of the auditor, and re-election of the independent voting rights representative. Shareholders will consider amendments to the Articles of Association to increase the capital band and conditional share capital, and will vote on future compensation for the board and executive management. The filing reiterates that investors should review existing SEC risk factors and notes that the press release is incorporated by reference into existing F-3 and S-8 registration statements.
Addex Therapeutics Ltd files its annual report on Form 20-F, highlighting a development-stage biotech business with ongoing losses and tight liquidity. The company incurred an accumulated loss of CHF 360 million since inception and reported a net loss of CHF 6.7 million for the year ended December 31, 2025, compared to a net profit of CHF 7.1 million a year earlier, when results benefited from a business sale.
As of December 31, 2025, Addex held cash and cash equivalents of CHF 1.6 million and expects this to fund operations only through mid‑June 2026, so it will need significant additional capital from partnerships, IP monetization and equity offerings. The company sold its allosteric modulator discovery platform and certain preclinical programs to Neurosterix in April 2024 for CHF 5.0 million and a 20% equity stake, and now relies heavily on partners such as Indivior and Neurosterix for development, infrastructure and potential milestone revenue. The filing details extensive risks around financing, regulatory approvals, reliance on third parties, intellectual property, data protection, healthcare policy changes and potential Nasdaq delisting pressure.
Addex Therapeutics reported full-year 2025 results with a net loss of CHF 6.7 million, compared with a profit of CHF 7.1 million in 2024, and cash and cash equivalents of CHF 1.6 million at December 31, 2025. Income from continuing operations fell to CHF 0.2 million as the research phase of the Indivior collaboration ended mid-2024. R&D expenses declined to CHF 0.7 million, while G&A remained stable at CHF 2.3 million. Losses from associates increased to CHF 4.0 million due to its 20% stake in Neurosterix US Holdings LLC. Shareholders’ equity decreased to CHF 4.8 million.
Operationally, Addex advanced its GABAB PAM program for chronic cough, progressed dipraglurant (an mGlu5 NAM) toward clinical studies in brain injury recovery, and regained rights to the Phase 2 mGlu2 PAM asset ADX71149. It also entered an option and collaboration agreement with Sinntaxis on mGlu5 NAM for brain injury and maintained a strategic investment portfolio, including Neurosterix and Stalicla. The company scheduled a conference call on April 30, 2026, to discuss these results and its pipeline progress.
Addex Therapeutics filed a Form 6-K to furnish a press release highlighting new preclinical results for its GABAB positive allosteric modulator (PAM) candidate in an idiopathic pulmonary fibrosis (IPF)-related chronic cough model. In bleomycin-exposed animals, once-daily dosing produced robust and sustained reductions in cough frequency and longer cough latency, along with improved lung pathology measures such as lower Ashcroft scores and less affected lung tissue. The compound showed a favorable safety profile with stable respiratory rate and body temperature and was well tolerated, supporting its potential for chronic use in chronic cough. The company also reiterates broader work on allosteric modulators in neurological and related disorders.
Addex Therapeutics reported that its spin-out company Neurosterix remains on track to complete a Phase 1 clinical study of NTX-253 for schizophrenia in Q2 2026. NTX-253 is an oral, potent, selective positive allosteric modulator of the muscarinic M4 receptor, aiming to treat schizophrenia by indirectly modulating dopamine signaling.
The Phase 1 program includes single ascending dose and multiple ascending dose components in healthy adults and adults with stable schizophrenia, assessing safety, tolerability, pharmacokinetics, food effects and cerebrospinal fluid exposure. Neurosterix, spun out of Addex in April 2024, raised $65 million in Series A financing, and Addex retains a 20% equity interest in the company.
Addex Therapeutics reported new preclinical data showing its novel GABAB positive allosteric modulator (PAM) produced robust anti-tussive, or cough-suppressing, activity in a non-human primate chronic cough model. The candidate significantly reduced citric acid-induced cough frequency with efficacy similar to baclofen.
Previously reported guinea pig data showed the same GABAB PAM reduced cough frequency, increased cough latency and did not show tolerance after sub-chronic treatment, with antitussive effects appearing superior to nalbuphine, baclofen, codeine and a P2X3 inhibitor. The compound also demonstrated better tolerability and a wider therapeutic margin than nalbuphine, baclofen or codeine, and similar tolerability to a P2X3 inhibitor based on respiratory rate.
Addex is advancing this GABAB PAM program for chronic cough alongside other allosteric modulator programs, including its lead candidate dipraglurant for brain injury recovery and partnered GABAB PAM development in substance use disorders.
Addex Therapeutics Ltd. director and chief medical officer Roger Mills reported his initial holdings. He directly owns 785,976 shares of Common Stock listed on the SIX Swiss Exchange and holds stock options over 50,000 shares, exercisable at $0.0640 per share.
The options began vesting in equal monthly installments over four years from the exercisable date of January 8, 2024 and expire on January 7, 2034. The exercise price is shown in U.S. dollars using an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.
Addex Therapeutics Ltd. director Vincent Michael Lawton has filed a Form 3 reporting his initial beneficial ownership in the company. He holds 2,507,987 shares of Common Stock listed on the SIX Swiss Exchange and a stock option award over 501,598 shares of Common Stock.
The stock options carry an exercise price of $0.064 per share, based on a CHF-to-USD exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026. These options began vesting in equal monthly installments over a four-year period starting January 8, 2024 and expire on January 7, 2034.